ホーム>>Lipids>> P450>>Metyrapone

Metyrapone (Synonyms: NSC 25265, SU 4885)

カタログ番号GC17411

メチラポン (Su-4885) は、強力な経口活性 11β-ヒドロキシラーゼ阻害剤であり、オートファジー活性化剤であり、アルドステロンの産生も阻害します。

Products are for research use only. Not for human use. We do not sell to patients.

Metyrapone 化学構造

Cas No.: 54-36-4

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$44.00
在庫あり
100mg
$48.00
在庫あり
500mg
$144.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com


顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Metyrapone is a potent oral 11β-hydroxylase inhibitor and autophagy activator that also inhibits aldosterone production. It can be used in the study of depression, atherosclerosis and cancer[1,2].

Metyrapone (100μM; 2h) hyperactivates autophagy in HepG2, and delays the activation of apoptosis at severe endoplasmic reticulum (ER) stress[3]. In H295R cells, treatment with Metyrapone (20μM; 48h) for 48 hours significantly reduced cortisol levels, which were 25.2±4.3μg/L in untreated cells and decreased to 18.9±0.3μg/L after Metyrapone treatment[4].

Neuronal loss in the hippocampal CAl region was significantly reduced in the 4VO model in rats administered Metyrapone (200 mg/kg; sc; 30 min before ischaemia)[5]. There was significant impairment of ovarian and uterine development in the young female Metyrapone-treated (100mg/kg; ip; 30d) mice with the incidence of corpora lutea being reduced 82%. Seminal vesicle and body weights were significantly reduced in juvenile males[6]. Metyrapone (100mg/kg; ip; 4 weeks) treatment reduced the relative mRNA expression levels of phosphoenolpyruvate carboxykinase, a gluconeogenic GR target gene, in the liver and was associated with increased relative mRNA expression levels of the adrenal high-density lipoprotein receptor, SR-BI, and the steroidogenic enzymes, CYP11A1 and CYP11B[7].

References:
[1]. Roozendaall B, Bohus B, McGaugh J L. Dose-dependent suppression of adrenocortical activity with metyrapone: effects on emotion and memory[J]. Psychoneuroendocrinology, 1996, 21(8): 681-693.
[2]. Jahn H, Schick M, Kiefer F, et al. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial[J]. Archives of general psychiatry, 2004, 61(12): 1235-1244.
[3]. Holczer M, Márton M, Kurucz A, et al. A comprehensive systems biological study of autophagy‐apoptosis crosstalk during endoplasmic reticulum stress[J]. BioMed research international, 2015, 2015(1): 319589.
[4]. Germano A, Saba L, De Francia S, et al. CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells[J]. PloS one, 2018, 13(5): e0196931.
[5]. Lidhar N K, Darvish-Ghane S, Sivaselvachandran S, et al. Prelimbic cortex glucocorticoid receptors regulate the stress-mediated inhibition of pain contagion in male mice[J]. Neuropsychopharmacology, 2021, 46(6): 1183-1193.
[6]. Pasley J N, McKinney R D, Blue L R. Effects of metyrapone on reproductive organs of house mice[J]. Proceedings of the Society for Experimental Biology and Medicine, 1975, 148(2): 333-336.
[7]. van der Sluis R J, van den Aardweg T, Sijsenaar T J P, et al. Metyrapone Treatment Protects Low-Density Lipoprotein Receptor Knockout Mice against Hypercorticosteronemia Development without Changing Atherosclerosis Susceptibility[J]. Biomolecules, 2023, 13(9): 1287.

レビュー

Review for Metyrapone

Average Rating: 5 ★★★★★ (Based on Reviews and 29 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Metyrapone

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.